Aptorum Group Ltd Cl A (APM)

$1.97 -0.25 (-11.06%)
Market Cap 10.53M
Revenue (ttm) 0.00
Net Income (ttm) -4.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.28
Volume 506,600
Avg Vol 12,477,904
Day's Range N/A - N/A
Shares Out 5.35M
Stochastic %K 22%
Beta 0.18
Analysts Strong Buy
Price Target $80.00

Company Profile

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylo...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 8092 9299
Address:
17 Hanover Square, London, United Kingdom
Sw1ngb0t
Sw1ngb0t Sep. 1 at 1:43 PM
$SNGX $BTAI $APM I think these three are gearing up. Safe areas either way. $SNGX and $BTAI look ready to jump in. $APM waiting for a green day. I don't think $APM's humongous gap will fill but you never know...
0 · Reply
Bullbear1010101
Bullbear1010101 Sep. 1 at 1:01 AM
$APM yep 2.00
0 · Reply
Sw1ngb0t
Sw1ngb0t Aug. 31 at 10:23 PM
$SNGX $APM $BTAI $FOSL Sw1ngb0t's sexy swingers for next week
1 · Reply
Sw1ngb0t
Sw1ngb0t Aug. 31 at 9:32 PM
$APM $BTAI I think these are low risk now... I'd buy if I wasn't playing something else
1 · Reply
Sw1ngb0t
Sw1ngb0t Aug. 31 at 7:24 PM
went back a month and found some better value: $SNGX - ready to go... looks nice $BTAI - $8.23+ $APM - $6.67+ $BNR - $13.52+ (china stock) $CRML - $7.69+ last four have pulled back enough, just waiting for a spark on the daily chart...i.e. something like below...and hopefully they give us time to get in :P
1 · Reply
DylanGFM
DylanGFM Aug. 29 at 9:45 AM
$MOVE $GMHS we need some volume on $APM .. $ONDS still holding well... I guess $SOGP doesn't want it yet
1 · Reply
Zackal
Zackal Aug. 28 at 11:52 AM
$APM buying some WAI too
0 · Reply
Codexxx
Codexxx Aug. 28 at 11:01 AM
$APM Sorry I dont catch.. Dont see how much they covered? Tnx
0 · Reply
Zackal
Zackal Aug. 28 at 12:11 AM
$APM bought some
0 · Reply
StocktwitsAragorn
StocktwitsAragorn Aug. 27 at 9:59 PM
$APM Covered short position! https://www.stockscores.com/charts/charts/?ticker=apm
1 · Reply
Latest News on APM
Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

Aug 21, 2025, 11:39 AM EDT - 11 days ago

Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

Aug 21, 2025, 7:07 AM EDT - 11 days ago

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

Andean Precious Metals Corp. (ANPMF) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 12:13 PM EDT - 19 days ago

Andean Precious Metals Corp. (ANPMF) Q2 2025 Earnings Call Transcript

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aug 4, 2025, 8:15 AM EDT - 4 weeks ago

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Jul 16, 2025, 8:38 AM EDT - 6 weeks ago

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 16, 2025, 12:27 PM EDT - 4 months ago

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Jan 8, 2025, 11:30 AM EST - 8 months ago

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Jan 2, 2025, 10:55 AM EST - 8 months ago

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Dec 20, 2024, 4:00 PM EST - 9 months ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Apr 30, 2024, 9:15 AM EDT - 1 year ago

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Mar 6, 2024, 8:00 AM EST - 1 year ago

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Dec 22, 2023, 4:30 PM EST - 1 year ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Dec 21, 2023, 4:30 PM EST - 1 year ago

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Nov 16, 2023, 11:00 AM EST - 1 year ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aug 10, 2023, 2:57 AM EDT - 2 years ago

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Jun 22, 2023, 8:00 AM EDT - 2 years ago

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Jun 9, 2023, 4:30 PM EDT - 2 years ago

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

May 5, 2023, 4:31 PM EDT - 2 years ago

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

May 1, 2023, 8:00 AM EDT - 2 years ago

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Apr 28, 2023, 9:44 AM EDT - 2 years ago

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

Mar 17, 2023, 8:15 AM EDT - 2 years ago

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ASPI

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Mar 3, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Mar 3, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Mar 2, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Feb 10, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Feb 6, 2023, 10:08 AM EST - 2 years ago

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Aptorum Group Announces 1-for-10 Reverse Stock Split

Jan 20, 2023, 8:22 AM EST - 2 years ago

Aptorum Group Announces 1-for-10 Reverse Stock Split

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Jan 4, 2023, 9:00 AM EST - 2 years ago

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Dec 22, 2022, 8:00 AM EST - 2 years ago

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Dec 16, 2022, 8:00 AM EST - 2 years ago

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Dec 9, 2022, 7:00 AM EST - 2 years ago

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Nov 25, 2022, 8:30 AM EST - 3 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Nov 25, 2022, 8:00 AM EST - 3 years ago

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Nov 18, 2022, 5:30 PM EST - 3 years ago

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Nov 8, 2022, 6:00 AM EST - 3 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Sep 30, 2022, 7:42 PM EDT - 3 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Sep 15, 2022, 8:07 AM EDT - 3 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Sep 15, 2022, 7:00 AM EDT - 3 years ago

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

Aug 25, 2022, 8:31 PM EDT - 3 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

May 17, 2022, 8:13 AM EDT - 3 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

May 2, 2022, 8:00 AM EDT - 3 years ago

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

Apr 29, 2022, 4:00 PM EDT - 3 years ago

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Apr 25, 2022, 9:30 AM EDT - 3 years ago

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Apr 22, 2022, 8:00 AM EDT - 3 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies

Feb 11, 2022, 3:09 PM EST - 3 years ago

Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Jan 20, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Jan 18, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

Sw1ngb0t
Sw1ngb0t Sep. 1 at 1:43 PM
$SNGX $BTAI $APM I think these three are gearing up. Safe areas either way. $SNGX and $BTAI look ready to jump in. $APM waiting for a green day. I don't think $APM's humongous gap will fill but you never know...
0 · Reply
Bullbear1010101
Bullbear1010101 Sep. 1 at 1:01 AM
$APM yep 2.00
0 · Reply
Sw1ngb0t
Sw1ngb0t Aug. 31 at 10:23 PM
$SNGX $APM $BTAI $FOSL Sw1ngb0t's sexy swingers for next week
1 · Reply
Sw1ngb0t
Sw1ngb0t Aug. 31 at 9:32 PM
$APM $BTAI I think these are low risk now... I'd buy if I wasn't playing something else
1 · Reply
Sw1ngb0t
Sw1ngb0t Aug. 31 at 7:24 PM
went back a month and found some better value: $SNGX - ready to go... looks nice $BTAI - $8.23+ $APM - $6.67+ $BNR - $13.52+ (china stock) $CRML - $7.69+ last four have pulled back enough, just waiting for a spark on the daily chart...i.e. something like below...and hopefully they give us time to get in :P
1 · Reply
DylanGFM
DylanGFM Aug. 29 at 9:45 AM
$MOVE $GMHS we need some volume on $APM .. $ONDS still holding well... I guess $SOGP doesn't want it yet
1 · Reply
Zackal
Zackal Aug. 28 at 11:52 AM
$APM buying some WAI too
0 · Reply
Codexxx
Codexxx Aug. 28 at 11:01 AM
$APM Sorry I dont catch.. Dont see how much they covered? Tnx
0 · Reply
Zackal
Zackal Aug. 28 at 12:11 AM
$APM bought some
0 · Reply
StocktwitsAragorn
StocktwitsAragorn Aug. 27 at 9:59 PM
$APM Covered short position! https://www.stockscores.com/charts/charts/?ticker=apm
1 · Reply
Codexxx
Codexxx Aug. 27 at 6:35 PM
$APM on this volume shorts are stuck. Lets see. 3 days ago short volume was 200 mil. Today 400 k. Total volume. Lets how they will cover???
0 · Reply
Camelinvesting
Camelinvesting Aug. 27 at 6:19 PM
$APM tomorrow buying here. The chart looks sexy 😍
0 · Reply
SpartanVI
SpartanVI Aug. 27 at 11:13 AM
$GLE $SPRC $PFSA $IMG $APM Agreed
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Aug. 27 at 11:12 AM
$GLE Watching 0.77$ break for retest of 0.87$+. Over that, it goes to 1$ Lots of good plays lately $SPRC $PFSA $IMG $APM All these plays went up BIG!! GLE next ?
1 · Reply
NextLeg
NextLeg Aug. 26 at 9:03 PM
$APM Bottom was hit with a curl today. Looking for volume and a nice spike from here.
0 · Reply
Camelinvesting
Camelinvesting Aug. 26 at 8:38 PM
$APM on watch
0 · Reply
Zackal
Zackal Aug. 26 at 7:52 PM
$APM ill buy soon.
0 · Reply
_www_larval_com_
_www_larval_com_ Aug. 26 at 3:59 PM
$APM just shot 3% higher to 7% (~1Mv) a moment ago, follow for more volatility.
0 · Reply
Lwschadler
Lwschadler Aug. 26 at 3:53 PM
$APM In
0 · Reply
TheBidenDuffleBagBoy
TheBidenDuffleBagBoy Aug. 26 at 2:06 PM
$APM this will be printing money in Q4 when the merger is fully complete
0 · Reply
TheBidenDuffleBagBoy
TheBidenDuffleBagBoy Aug. 26 at 2:06 PM
$APM
0 · Reply
Rampageusa
Rampageusa Aug. 26 at 1:56 PM
$APM 5/7++
0 · Reply